Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential

  title={Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential},
  author={Jan H. von der Th{\"u}sen and Johan Kuiper and Th J C van Berkel and Erik A. L. Biessen},
  journal={Pharmacological Reviews},
  pages={133 - 166}
Interleukins are considered to be key players in the chronic vascular inflammatory response that is typical of atherosclerosis. Thus, the expression of proinflammatory interleukins and their receptors has been demonstrated in atheromatous tissue, and the serum levels of several of these cytokines have been found to be positively correlated with (coronary) arterial disease and its sequelae. In vitro studies have confirmed the involvement of various interleukins in pro-atherogenic processes, such… 

Figures and Tables from this paper

Expression and function of anti-inflammatory interleukins: the other side of the vascular response to injury.
It is proposed that expression of immunomodulatory cytokines by activated vasculature may represent an auto-regulatory feed back mechanism to promote resolution of the vascular response to injury.
Cytokines in atherosclerosis: pathogenic and regulatory pathways.
Based on the current knowledge of the role of cytokines in atherosclerosis, some novel therapeutic strategies to combat this disease are proposed and the potential of circulating cytokine levels as biomarkers of coronary artery disease is discussed.
Pro- and Anti-Inflammatory Cytokine Networks in Atherosclerosis
The cellular protagonists of atherosclerosis are described and the cytokines which have been identified as produced by and directly affecting dysfunction of these cells are described, with emphasis placed on inflammatory cytokines and their effects on atherogenesis.
Cytokines and atherosclerosis: a comprehensive review of studies in mice
This survey summarizes the currently available information from mouse studies on the contribution of a specified group of cytokines expressed in atherosclerotic lesions and concludes that only for a few cytokines there is sufficient consistent data allowing classifying them as typically proatherogenic (IL-1,IL-12, IL-18, MIF, IFN-γ, TNF-α, and M-CSF) or anti-atherogensic ( IL-10).
Attenuation of Experimental Atherosclerosis by Interleukin-19
Data indicate that IL‐19 is a potent inhibitor of experimental atherosclerosis, with diverse mechanisms including immune cell polarization, decrease in macrophage adhesion, and decrease in gene expression.
Novel control of cAMP-regulated transcription in vascular endothelial cells.
New molecular mechanisms by which the cAMP/Epac1 (exchange protein directly activated by cAMP 1)/Rap1 pathway can initiate a rigorous programme of protective anti-inflammatory responses in VECs will inform the development of the next generation of pharmaceuticals specifically designed to combat endothelial inflammation associated with cardiovascular disease.
Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors
The findings suggest that cytokines in the IL-1 family may represent therapeutic targets in CAD and the ability of statins to modulate these cytokine in an anti-inflammatory direction underscores their immunomodulatory potential.
Anti-Inflammatory Effects of Interleukin-19 in Vascular Disease
The role of inflammatory cytokines and lymphocyte Th1/Th2 polarity in vascular inflammation, with a focus on atherosclerotic vascular disease is examined and the possibility that IL-19 could represent a potential therapeutic to combat vascular inflammatory disease is presented.


Protective role of interleukin-10 in atherosclerosis.
It is shown that IL-10-deficient C57BL/6J mice fed an atherogenic diet and raised under specific pathogen-free conditions exhibit a significant 3-fold increase in lipid accumulation compared with wild-type mice, which underscores the critical roles ofIL-10 in both atherosclerotic lesion formation and stability.
Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque
In the late stages of the disease, matrix metalloproteinases derived from macrophages or smooth-muscle cells themselves may contribute to weakening of the fibrous cap in the vulnerable shoulder area, promoting plaque rupture and occlusive thrombosis, culminating in the dramatic clinical manifestations of atherosclerosis, including myocardial infarction and stroke.
IL-10: An "immunologic scalpel" for atherosclerosis?
  • R. Terkeltaub
  • Medicine, Biology
    Arteriosclerosis, thrombosis, and vascular biology
  • 1999
A novel chapter in an evolving story on the potential modulatory role of IL-10 in atherosclerosis is presented, which describes how the cytokine downregulates IL-12 production and inhibits Th1 immune responses, which would normally be associated with IL-2 and interferon-γ (IFN-γ) expression and with T-cell and macrophage activation.
Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein
The role of the potent endothelium-derived vasoactive factor endothelin-1 (ET-1) and the inflammatory cytokine interleukin-6 (IL-6) as mediators ofCRP-induced proatherogenic processes is examined and Bosentan may be useful in decreasing CRP-mediated vascular disease.
Interleukin-3 Stimulates Migration and Proliferation of Vascular Smooth Muscle Cells: A Potential Role in Atherogenesis
IL-3, expressed by activated T lymphocytes infiltrating early and advanced atherosclerotic plaques, may sustain the atherosclerosis process either directly, by activating SMC migration and proliferation, or indirectly, via VEGF production.
Anti-Inflammatory Mechanisms in the Vascular Wall
The role of vascular cells during inflammation is critical and is of particular importance in inflammatory diseases, including atherosclerosis, ischemia/reperfusion, and septic shock, as well as some angiogenic and growth factors.
Reduction of atherosclerosis in mice by inhibition of CD40 signalling
Treatment with antibody against mouse CD40L limited atherosclerosis in mice lacking the receptor for low-density lipoprotein that had been fed a high-cholesterol diet for 12 weeks and indicated a role for CD40 signalling during atherogenesis in hyperlipidaemic mice.
Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability
These results suggest, for the first time, a major role for IL-18 in atherosclerotic plaque destabilization leading to acute ischemic syndromes.
Interleukin-18/Interleukin-18 Binding Protein Signaling Modulates Atherosclerotic Lesion Development and Stability
In vivo electrotransfer of an expression-plasmid DNA encoding for murine IL-18 binding protein (BP) (the endogenous inhibitor of IL- 18) prevents fatty streak development in the thoracic aorta of apoE knockout mice and slows progression of advanced atherosclerotic plaques in the aortic sinus.